Complete List of All AI Companies Under $2 Billion Market Cap

Page 15 of 45

33. Tevogen Bio Holdings Inc. (NASDAQ:TVGN)

Market Capitalization: $213.56 Million

Number of Hedge Fund Holders: 10

Tevogen Bio Holdings Inc. (NASDAQ:TVGN) is a clinical-stage immunotherapy company focused on developing precision T-cell therapies using CD8+ cytotoxic T lymphocytes to treat infectious diseases, cancers, and neurological disorders. The company aims to address unmet medical needs with off-the-shelf, genetically unmodified therapies. The company is revolutionizing AI in the biopharma industry. Tevogen has shown positive safety data in its clinical trials and owns significant intellectual property, including patents related to AI, which support its innovations in immunotherapy and patient accessibility.

In December 2024, Tevogen Bio (NASDAQ:TVGN) filed for a new patent titled “Systems And Methods For Predicting Immunologically Active Peptides With Machine Learning Models,” expanding its intellectual property portfolio. The company launched Tevogen.AI in October 2023 to accelerate drug discovery, development, manufacturing, and patient access, benefiting both its own efforts and other biotech companies.

In May 2024, the company partnered with Microsoft through the Microsoft for Startups program, gaining access to AI expertise and resources. By November 2024, AI-driven machine learning had contributed to target identification for Human Papilloma Virus, marking the beginning of Tevogen Bio’s oncology treatment pipeline. CEO Dr. Ryan Saadi, commented:

“When combining our expertise across biopharma and artificial intelligence, we anticipate becoming a leader in the field with breakthroughs to follow.”

Page 15 of 45